{"id":"plerixafor","rwe":[],"_fda":{"id":"fec4102e-2c66-433f-ab6c-7f420b4c3a86","set_id":"0ed08d2b-5051-46b2-aa37-1d6275bf9003","openfda":{"nui":["N0000178326","N0000178324"],"unii":["S915P5499N"],"route":["SUBCUTANEOUS"],"rxcui":["828700","828703"],"spl_id":["fec4102e-2c66-433f-ab6c-7f420b4c3a86"],"brand_name":["Mozobil"],"spl_set_id":["0ed08d2b-5051-46b2-aa37-1d6275bf9003"],"package_ndc":["0024-5862-01"],"product_ndc":["0024-5862"],"generic_name":["PLERIXAFOR"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_pe":["Increased Hematopoietic Stem Cell Mobilization [PE]"],"substance_name":["PLERIXAFOR"],"pharm_class_epc":["Hematopoietic Stem Cell Mobilizer [EPC]"],"manufacturer_name":["Sanofi-Aventis U.S. LLC"],"application_number":["NDA022311"],"is_original_packager":[true]},"version":"24","pregnancy":["8.1 Pregnancy Risk Summary Limited available data with Mozobil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. In animal reproduction studies, subcutaneous administration of plerixafor to pregnant rats during organogenesis at doses 10-times the maximum recommended human doses resulted in embryo-fetal mortality, structural abnormalities, and alterations to growth [see Data ] . Advise pregnant women of the potential risk to the fetus. Advise women of reproductive potential to avoid becoming pregnant while receiving treatment with Mozobil [see Warnings and Precautions (5.6) ]. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriages for the indicated population is unknown. Data Animal data Plerixafor administered to pregnant rats induced embryo-fetal toxicity, including fetal death, increased resorptions and postimplantation loss, decreased fetal weights, anophthalmia, shortened digits, cardiac interventricular septal defect, ringed aorta, globular heart, hydrocephaly, dilatation of olfactory ventricles, and retarded skeletal development. Embryo-fetal toxicities occurred mainly at a dose of 90 mg/m 2 (approximately 10 times the recommended human dose of 0.24 mg/kg when compared on a mg/m 2 basis)."],"overdosage":["10 OVERDOSAGE Based on limited data at doses above the recommended dose of 0.24 mg/kg SC, the frequency of gastrointestinal disorders, vasovagal reactions, orthostatic hypotension, and/or syncope may be higher."],"description":["11 DESCRIPTION Mozobil (plerixafor) injection is a sterile, preservative-free, clear, colorless to pale-yellow, isotonic solution for subcutaneous injection. Each mL of the sterile solution contains 20 mg of plerixafor. Each single-dose vial is filled to deliver 1.2 mL of the sterile solution that contains 24 mg of plerixafor and 5.9 mg of sodium chloride in Water for Injection adjusted to a pH of 6.0 to 7.5 with hydrochloric acid and with sodium hydroxide, if required. Plerixafor is a hematopoietic stem cell mobilizer with a chemical name 1,4-Bis((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzene. It has the molecular formula C 28 H 54 N 8 . The molecular weight of plerixafor is 502.79 g/mol. The structural formula is provided in Figure 1 . Figure 1: Structural Formula Plerixafor is a white to off-white crystalline solid. It is hygroscopic. Plerixafor has a typical melting point of 131.5°C. The partition coefficient of plerixafor between 1-octanol and pH 7 aqueous buffer is <0.1. Figure 1: Structural Formula"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Mozobil ® (plerixafor) injection 24 mg/1.2 mL (20 mg/mL) is a sterile, preservative-free, clear, colorless to pale-yellow solution supplied in a 2 mL clear glass single-dose vial. NDC Number: 0024-5862-01 Store at 25°C (77°F); excursions permitted to 15°C–30°C (59°F–86°F) [see USP Controlled Room Temperature]."],"geriatric_use":["8.5 Geriatric Use Of the total number of subjects in controlled clinical studies of Mozobil, 24% were 65 and over, while 0.8% were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Since plerixafor is mainly excreted by the kidney, no dose modifications are necessary in elderly individuals with normal renal function. In general, care should be taken in dose selection for elderly patients due to the greater frequency of decreased renal function with advanced age. Dosage adjustment in elderly patients with CL CR less than or equal to 50 mL/min is recommended [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] ."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of Mozobil have not been established in pediatric patients. Effectiveness was not demonstrated in a single phase 1/2 randomized, open-label, comparative study of Mozobil plus standard regimens for mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Forty-five pediatric patients ages 1 to <17 years with solid tumors or lymphoma were randomized 2:1 to Mozobil in addition to standard mobilization regimens (N=30) or standard mobilization regimens alone (N=15) (comparator arm). No new safety signals were observed in pediatric patients in this trial. The day prior to the first apheresis, median peripheral blood CD34+ counts were 35 × 10 6 cells/L in the comparator arm and 15 × 10 6 cells/L in the Mozobil arm. On the day of the first apheresis, median peripheral blood CD34+ counts were 64 × 10 6 cells/L in the comparator arm and 77 × 10 6 cells/L in the Mozobil arm. Plerixafor exposure, shown as AUC, in pediatric patients aged 12 to 18 years was within the range of values previously observed in adults, while the AUC of plerixafor in pediatric patients aged 2 to 12 years was 67% to 87% of that observed in adults, given the same adult dose (0.24 mg/kg)."],"effective_time":"20250922","clinical_studies":["14 CLINICAL STUDIES The efficacy and safety of Mozobil in conjunction with filgrastim in non-Hodgkin's lymphoma (NHL) Study AMD 3100-3101 (referred to as study 1) (NCT00103610) and multiple myeloma (MM) Study AMD 3100-3102 (referred to as study 2) (NCT00103662) were evaluated in two placebo-controlled studies (Studies 1 and 2). Patients were randomized to receive either Mozobil 0.24 mg/kg or placebo on each evening prior to apheresis. Patients received daily morning doses of filgrastim 10 mcg/kg for 4 days prior to the first dose of Mozobil or placebo and on each morning prior to apheresis. Two hundred and ninety-eight (298) NHL patients were included in the primary efficacy analyses for Study 1. The mean age was 55 years (range 29–75) and 58 years (range 22–75) in the Mozobil and placebo groups, respectively, and 93% of subjects were Caucasian. In study 2, 302 patients with MM were included in the primary efficacy analyses. The mean age (58 years) and age range (28–75) were similar in the Mozobil and placebo groups, and 81% of subjects were Caucasian. In Study 1, 59% of NHL patients who were mobilized with Mozobil and filgrastim collected ≥5 × 10 6 CD34+ cells/kg from the peripheral blood in four or fewer apheresis sessions, compared with 20% of patients who were mobilized with placebo and filgrastim (p <0.001). Other CD34+ cell mobilization outcomes showed similar findings (Table 5). Table 5: Study 1 Efficacy Results - CD34+ Cell Mobilization in NHL Patients Efficacy Endpoint Mozobil and Filgrastim (n=150) Placebo and Filgrastim (n=148) p-value p-value calculated using Pearson's Chi-Squared test Patients achieving ≥5 × 10 6 cells/kg in ≤4 apheresis days 89 (59%) 29 (20%) <0.001 Patients achieving ≥2 × 10 6 cells/kg in ≤4 apheresis days 130 (87%) 70 (47%) <0.001 The median number of days to reach ≥5 × 10 6 CD34+ cells/kg was 3 days for the Mozobil group and not evaluable for the placebo group. Table 6 presents the proportion of patients who achieved ≥5 × 10 6 CD34+ cells/kg by apheresis day. Table 6: Study 1 Efficacy Results – Proportion of Patients Who Achieved ≥5 × 10 6 CD34+ cells/kg by Apheresis Day in NHL Patients Days Proportion Percents determined by Kaplan Meier method in Mozobil and Filgrastim (n=147 n includes all patients who received at least one day of apheresis ) Proportion in Placebo and Filgrastim (n=142 ) 1 27.9% 4.2% 2 49.1% 14.2% 3 57.7% 21.6% 4 65.6% 24.2% In Study 2, 72% of MM patients who were mobilized with Mozobil and filgrastim collected ≥6 × 10 6 CD34+ cells/kg from the peripheral blood in two or fewer apheresis sessions, compared with 34% of patients who were mobilized with placebo and filgrastim (p <0.001). Other CD34+ cell mobilization outcomes showed similar findings (Table 7). Table 7: Study 2 Efficacy Results – CD34+ Cell Mobilization in Multiple Myeloma Patients Efficacy Endpoint Mozobil and Filgrastim (n=148) Placebo and Filgrastim (n=154) p-value p-value calculated using Pearson's Chi-Squared test Patients achieving ≥6 × 10 6 cells/kg in ≤2 apheresis days 106 (72%) 53 (34%) <0.001 Patients achieving ≥6 × 10 6 cells/kg in ≤4 apheresis days 112 (76%) 79 (51%) <0.001 Patients achieving ≥2 × 10 6 cells/kg in ≤4 apheresis days 141 (95%) 136 (88%) 0.028 The median number of days to reach ≥6 × 10 6 CD34+ cells/kg was 1 day for the Mozobil group and 4 days for the placebo group. Table 8 presents the proportion of patients who achieved ≥6 × 10 6 CD34+ cells/kg by apheresis day. Table 8: Study 2 – Proportion of Patients Who Achieved ≥6 × 10 6 CD34+ cells/kg by Apheresis Day in MM Patients Days Proportion Percents determined by Kaplan Meier method in Mozobil and Filgrastim (n=144 n includes all patients who received at least one day of apheresis ) Proportion in Placebo and Filgrastim (n=150 ) 1 54.2% 17.3% 2 77.9% 35.3% 3 86.8% 48.9% 4 86.8% 55.9% Multiple factors can influence time to engraftment and graft durability following stem cell transplantation. For transplanted patients in the Phase 3 studies, time to neutrophil and platelet engraftment and graft durability were similar across the treatment groups."],"pharmacodynamics":["12.2 Pharmacodynamics Data on the fold increase in peripheral blood CD34+ cell count (cells/mcL) by apheresis day were evaluated in two placebo-controlled clinical studies in patients with NHL and MM (Study 1 and Study 2, respectively). The fold increase in CD34+ cell count (cells/mcL) over the 24-hour period starting from the day prior to the first apheresis and ending the next morning just before the first apheresis is summarized in Table 3. During this 24-hour period, a single dose of Mozobil or placebo was administered 10 to 11 hours prior to apheresis. Table 3: Fold Increase in Peripheral Blood CD34+ Cell Count Following Pretreatment with Filgrastim and Administration of Plerixafor Study Mozobil and Filgrastim Placebo and Filgrastim Median Mean (SD) Median Mean (SD) Study 1 5.0 6.1 (5.4) 1.4 1.9 (1.5) Study 2 4.8 6.4 (6.8) 1.7 2.4 (7.3) In pharmacodynamic studies of Mozobil in healthy volunteers, peak mobilization of CD34+ cells was observed between 6 and 9 hours after administration. In pharmacodynamic studies of Mozobil in conjunction with filgrastim in healthy volunteers, a sustained elevation in the peripheral blood CD34+ count was observed from 4 to 18 hours after plerixafor administration with a peak CD34+ count between 10 and 14 hours. QT/QTc Prolongation There is no indication of a QT/QTc prolonging effect of Mozobil in single doses up to 0.40 mg/kg. In a randomized, double-blind, crossover study, 48 healthy subjects were administered a single subcutaneous dose of plerixafor (0.24 mg/kg and 0.40 mg/kg) and placebo. Peak concentrations for 0.40 mg/kg Mozobil were approximately 1.8-fold higher than the peak concentrations following the 0.24 mg/kg single subcutaneous dose."],"pharmacokinetics":["12.3 Pharmacokinetics The single-dose pharmacokinetics of plerixafor 0.24 mg/kg were evaluated in patients with NHL and MM following pretreatment with filgrastim (10 mcg/kg once daily for 4 consecutive days). Plerixafor exhibits linear kinetics between the 0.04 mg/kg to 0.24 mg/kg dose range. The pharmacokinetics of plerixafor was similar across clinical studies in healthy subjects who received plerixafor alone and NHL and MM patients who received plerixafor in combination with filgrastim. A population pharmacokinetic analysis incorporated plerixafor data from 63 subjects (NHL patients, MM patients, subjects with varying degrees of renal impairment, and healthy subjects) who received a single SC dose (0.04 mg/kg to 0.24 mg/kg) of plerixafor. A two-compartment disposition model with first order absorption and elimination was found to adequately describe the plerixafor concentration-time profile. Significant relationships between clearance and creatinine clearance (CL CR ), as well as between central volume of distribution and body weight were observed. The distribution half-life (t 1/2α ) was estimated to be 0.3 hours and the terminal population half-life (t 1/2β ) was 5.3 hours in patients with normal renal function. The population pharmacokinetic analysis showed that the mg/kg-based dosage results in an increased plerixafor exposure (AUC 0–24h ) with increasing body weight. In order to compare the pharmacokinetics and pharmacodynamics of plerixafor following 0.24 mg/kg-based and fixed (20 mg) doses, a follow-up trial was conducted in patients with NHL (N=61) who were treated with 0.24 mg/kg or 20 mg of plerixafor. The trial was conducted in patients weighing 70 kg or less. The fixed 20 mg dose showed 1.43-fold higher exposure (AUC 0–10h ) than the 0.24 mg/kg dose (Table 4). The fixed 20 mg dose also showed numerically higher response rate (5.2% [60.0% vs 54.8%] based on the local lab data and 11.7% [63.3% vs 51.6%] based on the central lab data) in attaining the target of ≥5 × 10 6 CD34+ cells/kg than the mg/kg-based dose. However, the median time to reach ≥5 × 10 6 CD34+ cells/kg was 3 days for both treatment groups, and the safety profile between the groups was similar. Based on these results, further analysis was conducted by FDA reviewers and a body weight of 83 kg was selected as an appropriate cut-off point to transition patients from fixed to weight based dosing. Table 4: Systemic Exposure (AUC 0–10h ) Comparisons of Fixed and Weight-Based Regimens Regimen Geometric Mean AUC Fixed 20 mg (n=30) 3991.2 0.24 mg/kg (n=31) 2792.7 Ratio (90% CI) 1.43 (1.32,1.54) There is limited experience with the 0.24 mg/kg dose of plerixafor in patients weighing above 160 kg. Therefore, the dose should not exceed that of a 160 kg patient (i.e., 40 mg/day if CL CR is greater than 50 mL/min and 27 mg/day if CL CR is less than or equal to 50 mL/min) [see Dosage and Administration (2.1 , 2.3) ] . Absorption Peak plasma concentrations occurred at approximately 30 to 60 minutes after a SC dose. Distribution Plerixafor is bound to human plasma proteins up to 58%. The apparent volume of distribution of plerixafor in humans is 0.3 L/kg demonstrating that plerixafor is largely confined to, but not limited to, the extravascular fluid space. Metabolism The metabolism of plerixafor was evaluated with in vitro assays. Plerixafor is not metabolized as shown in assays using human liver microsomes or human primary hepatocytes and does not exhibit inhibitory activity in vitro towards the major drug metabolizing cytochrome P450 enzymes (1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4/5). In in vitro studies with human hepatocytes, plerixafor does not induce CYP1A2, CYP2B6, or CYP3A4 enzymes. These findings suggest that plerixafor has a low potential for involvement in cytochrome P450-dependent drug-drug interactions. Elimination The major route of elimination of plerixafor is urinary. Following a 0.24 mg/kg dose in healthy volunteers with normal renal function, approximately 70% of the dose was excreted in the urine as the parent drug during the first 24 hours following administration. In studies with healthy subjects and patients, the terminal half-life in plasma ranges between 3 and 5 hours. At concentrations similar to what are seen clinically, plerixafor did not act as a substrate or inhibitor of P-glycoprotein in an in vitro study with MDCKII and MDCKII-MDR1 cell models. Special Populations Renal impairment Following a single 0.24 mg/kg SC dose, plerixafor clearance was reduced in subjects with varying degrees of renal impairment and was positively correlated with CL CR . The mean AUC 0–24h of plerixafor in subjects with mild (CL CR 51–80 mL/min), moderate (CL CR 31–50 mL/min), and severe (CL CR <31 mL/min) renal impairment was 7%, 32%, and 39% higher than healthy subjects with normal renal function, respectively. Renal impairment had no effect on C max . A population pharmacokinetic analysis indicated an increased exposure (AUC 0–24h ) in patients with moderate and severe renal impairment compared to patients with CL CR >50 mL/min. These results support a dose reduction of one-third in patients with moderate to severe renal impairment (CL CR ≤50 mL/min) in order to match the exposure in patients with normal renal function. The population pharmacokinetic analysis showed that the mg/kg-based dosage results in an increased plerixafor exposure (AUC 0–24h ) with increasing body weight; therefore, if CL CR is ≤50 mL/min the dose should not exceed 27 mg/day [see Dosage and Administration (2.3) ] . Since plerixafor is primarily eliminated by the kidneys, coadministration of plerixafor with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of plerixafor or the coadministered drug. The effects of coadministration of plerixafor with other drugs that are renally eliminated or are known to affect renal function have not been evaluated. Race Clinical data show similar plerixafor pharmacokinetics for Caucasians and African Americans, and the effect of other racial/ethnic groups has not been studied. Gender Clinical data show no effect of gender on plerixafor pharmacokinetics. Age Clinical data show no effect of age on plerixafor pharmacokinetics."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are discussed elsewhere in the labeling: Anaphylactic shock and hypersensitivity reactions [see Warnings and Precautions (5.1) ] Potential for tumor cell mobilization in leukemia patients [see Warnings and Precautions (5.2) ] Increased circulating leukocytes and decreased platelet counts [see Warnings and Precautions (5.3) ] Potential for tumor cell mobilization [see Warnings and Precautions (5.4) ] Splenic enlargement [see Warnings and Precautions (5.5) ] Most common adverse reactions (≥10%): diarrhea, nausea, fatigue, injection site reactions, headache, arthralgia, dizziness, and vomiting. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-877-4MOZOBIL or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most common adverse reactions (≥10%) reported in patients who received Mozobil in conjunction with filgrastim regardless of causality and more frequent with Mozobil than placebo during HSC mobilization and apheresis were diarrhea, nausea, fatigue, injection site reactions, headache, arthralgia, dizziness, and vomiting. Safety data for Mozobil in combination with filgrastim were obtained from two randomized placebo-controlled studies (301 patients) and 10 uncontrolled studies (242 patients). Patients were primarily treated with Mozobil at daily doses of 0.24 mg/kg SC. Median exposure to Mozobil in these studies was 2 days (range 1 to 7 days). In the two randomized studies in patients with NHL and MM, a total of 301 patients were treated in the Mozobil and filgrastim group and 292 patients were treated in the placebo and filgrastim group. Patients received daily morning doses of filgrastim 10 mcg/kg for 4 days prior to the first dose of Mozobil 0.24 mg/kg SC or placebo and on each morning prior to apheresis. The adverse reactions that occurred in ≥5% of the patients who received Mozobil regardless of causality and were more frequent with Mozobil than placebo during HSC mobilization and apheresis are shown in Table 2. Table 2: Adverse Reactions in ≥5% of Non-Hodgkin's Lymphoma and Multiple Myeloma Patients Receiving Mozobil and More Frequent than Placebo during HSC Mobilization and Apheresis Percent of Patients (%) Mozobil and Filgrastim (n=301) Placebo and Filgrastim (n=292) All Grades Grades based on criteria from the World Health Organization (WHO) Grade 3 Grade 4 All Grades Grade 3 Grade 4 Gastrointestinal disorders Diarrhea 37 <1 0 17 0 0 Nausea 34 1 0 22 0 0 Vomiting 10 <1 0 6 0 0 Flatulence 7 0 0 3 0 0 General disorders and administration site conditions Injection site reactions 34 0 0 10 0 0 Fatigue 27 0 0 25 0 0 Musculoskeletal and connective tissue disorders Arthralgia 13 0 0 12 0 0 Nervous system disorders Headache 22 <1 0 21 1 0 Dizziness 11 0 0 6 0 0 Psychiatric disorders Insomnia 7 0 0 5 0 0 In the randomized studies, 34% of patients with NHL or MM had mild to moderate injection site reactions at the site of subcutaneous administration of Mozobil. These included erythema, hematoma, hemorrhage, induration, inflammation, irritation, pain, paresthesia, pruritus, rash, swelling, and urticaria. Mild to moderate allergic reactions were observed in less than 1% of patients within approximately 30 min after Mozobil administration, including one or more of the following: urticaria (n=2), periorbital swelling (n=2), dyspnea (n=1) or hypoxia (n=1). Symptoms generally responded to treatments (e.g., antihistamines, corticosteroids, hydration or supplemental oxygen) or resolved spontaneously. Vasovagal reactions, orthostatic hypotension, and/or syncope can occur following subcutaneous injections. In Mozobil oncology and healthy volunteer clinical studies, less than 1% of subjects experienced vasovagal reactions following subcutaneous administration of Mozobil doses ≤0.24 mg/kg. The majority of these events occurred within 1 hour of Mozobil administration. Because of the potential for these reactions, appropriate precautions should be taken. Other adverse reactions in the randomized studies that occurred in <5% of patients but were reported as related to Mozobil during HSC mobilization and apheresis included abdominal pain, hyperhidrosis, abdominal distention, dry mouth, erythema, stomach discomfort, malaise, hypoesthesia oral, constipation, dyspepsia, and musculoskeletal pain. Hyperleukocytosis: In clinical trials, white blood cell counts of 100,000/mcL or greater were observed, on the day prior to or any day of apheresis, in 7% of patients receiving Mozobil and in 1% of patients receiving placebo. No complications or clinical symptoms of leukostasis were observed. 6.2 Postmarketing Experience In addition to adverse reactions reported from clinical trials, the following adverse reactions have been reported from postmarketing experience with Mozobil. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and Lymphatic System: Splenomegaly and splenic rupture Immune System Disorders: Anaphylactic reactions, including anaphylactic shock Psychiatric Disorders: Abnormal dreams and nightmares"],"contraindications":["4 CONTRAINDICATIONS Mozobil is contraindicated in patients with a history of hypersensitivity to plerixafor [see Warnings and Precautions (5.1) ] . Anaphylactic shock has occurred with use of Mozobil. History of hypersensitivity to Mozobil. ( 4 )"],"mechanism_of_action":["12.1 Mechanism of Action Plerixafor is an inhibitor of the CXCR4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1α (SDF-1α). SDF-1α and CXCR4 are recognized to play a role in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrow compartment. Once in the marrow, stem cell CXCR4 can act to help anchor these cells to the marrow matrix, either directly via SDF-1α or through the induction of other adhesion molecules. Treatment with plerixafor resulted in leukocytosis and elevations in circulating hematopoietic progenitor cells in mice, dogs and humans. CD34+ cells mobilized by plerixafor were capable of engraftment with long-term repopulating capacity up to one year in canine transplantation models."],"storage_and_handling":["Store at 25°C (77°F); excursions permitted to 15°C–30°C (59°F–86°F) [see USP Controlled Room Temperature]."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Plerixafor is an inhibitor of the CXCR4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1α (SDF-1α). SDF-1α and CXCR4 are recognized to play a role in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrow compartment. Once in the marrow, stem cell CXCR4 can act to help anchor these cells to the marrow matrix, either directly via SDF-1α or through the induction of other adhesion molecules. Treatment with plerixafor resulted in leukocytosis and elevations in circulating hematopoietic progenitor cells in mice, dogs and humans. CD34+ cells mobilized by plerixafor were capable of engraftment with long-term repopulating capacity up to one year in canine transplantation models. 12.2 Pharmacodynamics Data on the fold increase in peripheral blood CD34+ cell count (cells/mcL) by apheresis day were evaluated in two placebo-controlled clinical studies in patients with NHL and MM (Study 1 and Study 2, respectively). The fold increase in CD34+ cell count (cells/mcL) over the 24-hour period starting from the day prior to the first apheresis and ending the next morning just before the first apheresis is summarized in Table 3. During this 24-hour period, a single dose of Mozobil or placebo was administered 10 to 11 hours prior to apheresis. Table 3: Fold Increase in Peripheral Blood CD34+ Cell Count Following Pretreatment with Filgrastim and Administration of Plerixafor Study Mozobil and Filgrastim Placebo and Filgrastim Median Mean (SD) Median Mean (SD) Study 1 5.0 6.1 (5.4) 1.4 1.9 (1.5) Study 2 4.8 6.4 (6.8) 1.7 2.4 (7.3) In pharmacodynamic studies of Mozobil in healthy volunteers, peak mobilization of CD34+ cells was observed between 6 and 9 hours after administration. In pharmacodynamic studies of Mozobil in conjunction with filgrastim in healthy volunteers, a sustained elevation in the peripheral blood CD34+ count was observed from 4 to 18 hours after plerixafor administration with a peak CD34+ count between 10 and 14 hours. QT/QTc Prolongation There is no indication of a QT/QTc prolonging effect of Mozobil in single doses up to 0.40 mg/kg. In a randomized, double-blind, crossover study, 48 healthy subjects were administered a single subcutaneous dose of plerixafor (0.24 mg/kg and 0.40 mg/kg) and placebo. Peak concentrations for 0.40 mg/kg Mozobil were approximately 1.8-fold higher than the peak concentrations following the 0.24 mg/kg single subcutaneous dose. 12.3 Pharmacokinetics The single-dose pharmacokinetics of plerixafor 0.24 mg/kg were evaluated in patients with NHL and MM following pretreatment with filgrastim (10 mcg/kg once daily for 4 consecutive days). Plerixafor exhibits linear kinetics between the 0.04 mg/kg to 0.24 mg/kg dose range. The pharmacokinetics of plerixafor was similar across clinical studies in healthy subjects who received plerixafor alone and NHL and MM patients who received plerixafor in combination with filgrastim. A population pharmacokinetic analysis incorporated plerixafor data from 63 subjects (NHL patients, MM patients, subjects with varying degrees of renal impairment, and healthy subjects) who received a single SC dose (0.04 mg/kg to 0.24 mg/kg) of plerixafor. A two-compartment disposition model with first order absorption and elimination was found to adequately describe the plerixafor concentration-time profile. Significant relationships between clearance and creatinine clearance (CL CR ), as well as between central volume of distribution and body weight were observed. The distribution half-life (t 1/2α ) was estimated to be 0.3 hours and the terminal population half-life (t 1/2β ) was 5.3 hours in patients with normal renal function. The population pharmacokinetic analysis showed that the mg/kg-based dosage results in an increased plerixafor exposure (AUC 0–24h ) with increasing body weight. In order to compare the pharmacokinetics and pharmacodynamics of plerixafor following 0.24 mg/kg-based and fixed (20 mg) doses, a follow-up trial was conducted in patients with NHL (N=61) who were treated with 0.24 mg/kg or 20 mg of plerixafor. The trial was conducted in patients weighing 70 kg or less. The fixed 20 mg dose showed 1.43-fold higher exposure (AUC 0–10h ) than the 0.24 mg/kg dose (Table 4). The fixed 20 mg dose also showed numerically higher response rate (5.2% [60.0% vs 54.8%] based on the local lab data and 11.7% [63.3% vs 51.6%] based on the central lab data) in attaining the target of ≥5 × 10 6 CD34+ cells/kg than the mg/kg-based dose. However, the median time to reach ≥5 × 10 6 CD34+ cells/kg was 3 days for both treatment groups, and the safety profile between the groups was similar. Based on these results, further analysis was conducted by FDA reviewers and a body weight of 83 kg was selected as an appropriate cut-off point to transition patients from fixed to weight based dosing. Table 4: Systemic Exposure (AUC 0–10h ) Comparisons of Fixed and Weight-Based Regimens Regimen Geometric Mean AUC Fixed 20 mg (n=30) 3991.2 0.24 mg/kg (n=31) 2792.7 Ratio (90% CI) 1.43 (1.32,1.54) There is limited experience with the 0.24 mg/kg dose of plerixafor in patients weighing above 160 kg. Therefore, the dose should not exceed that of a 160 kg patient (i.e., 40 mg/day if CL CR is greater than 50 mL/min and 27 mg/day if CL CR is less than or equal to 50 mL/min) [see Dosage and Administration (2.1 , 2.3) ] . Absorption Peak plasma concentrations occurred at approximately 30 to 60 minutes after a SC dose. Distribution Plerixafor is bound to human plasma proteins up to 58%. The apparent volume of distribution of plerixafor in humans is 0.3 L/kg demonstrating that plerixafor is largely confined to, but not limited to, the extravascular fluid space. Metabolism The metabolism of plerixafor was evaluated with in vitro assays. Plerixafor is not metabolized as shown in assays using human liver microsomes or human primary hepatocytes and does not exhibit inhibitory activity in vitro towards the major drug metabolizing cytochrome P450 enzymes (1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4/5). In in vitro studies with human hepatocytes, plerixafor does not induce CYP1A2, CYP2B6, or CYP3A4 enzymes. These findings suggest that plerixafor has a low potential for involvement in cytochrome P450-dependent drug-drug interactions. Elimination The major route of elimination of plerixafor is urinary. Following a 0.24 mg/kg dose in healthy volunteers with normal renal function, approximately 70% of the dose was excreted in the urine as the parent drug during the first 24 hours following administration. In studies with healthy subjects and patients, the terminal half-life in plasma ranges between 3 and 5 hours. At concentrations similar to what are seen clinically, plerixafor did not act as a substrate or inhibitor of P-glycoprotein in an in vitro study with MDCKII and MDCKII-MDR1 cell models. Special Populations Renal impairment Following a single 0.24 mg/kg SC dose, plerixafor clearance was reduced in subjects with varying degrees of renal impairment and was positively correlated with CL CR . The mean AUC 0–24h of plerixafor in subjects with mild (CL CR 51–80 mL/min), moderate (CL CR 31–50 mL/min), and severe (CL CR <31 mL/min) renal impairment was 7%, 32%, and 39% higher than healthy subjects with normal renal function, respectively. Renal impairment had no effect on C max . A population pharmacokinetic analysis indicated an increased exposure (AUC 0–24h ) in patients with moderate and severe renal impairment compared to patients with CL CR >50 mL/min. These results support a dose reduction of one-third in patients with moderate to severe renal impairment (CL CR ≤50 mL/min) in order to match the exposure in patients with normal renal function. The population pharmacokinetic analysis showed that the mg/kg-based dosage results in an increased plerixafor exposure (AUC 0–24h ) with increasing body weight; therefore, if CL CR is ≤50 mL/min the dose should not exceed 27 mg/day [see Dosage and Administration (2.3) ] . Since plerixafor is primarily eliminated by the kidneys, coadministration of plerixafor with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of plerixafor or the coadministered drug. The effects of coadministration of plerixafor with other drugs that are renally eliminated or are known to affect renal function have not been evaluated. Race Clinical data show similar plerixafor pharmacokinetics for Caucasians and African Americans, and the effect of other racial/ethnic groups has not been studied. Gender Clinical data show no effect of gender on plerixafor pharmacokinetics. Age Clinical data show no effect of age on plerixafor pharmacokinetics."],"indications_and_usage":["1 INDICATIONS AND USAGE Mozobil is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM). Mozobil, a hematopoietic stem cell mobilizer, is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma or multiple myeloma. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Anaphylactic Shock and Serious Hypersensitivity Reactions have occurred. Monitor patients during and after completion of Mozobil administration. ( 5.1 ) Tumor Cell Mobilization in Leukemia Patients: Mozobil may mobilize leukemic cells and should not be used in leukemia patients. ( 5.2 ) Hematologic Effects: Increased circulating leukocytes and decreased platelet counts have been observed. Monitor blood cell counts and platelet counts during Mozobil use. ( 5.3 ) Potential for Tumor Cell Mobilization: Tumor cells may be released from marrow during HSC mobilization with Mozobil and filgrastim. Effect of reinfusion of tumor cells is unknown. ( 5.4 ) Splenic Rupture: Evaluate patients who report left upper abdominal and/or scapular or shoulder pain. ( 5.5 ) Embryo-Fetal Toxicity: Can cause fetal harm. Advise women not to become pregnant when taking Mozobil. ( 5.6 , 8.1 ) 5.1 Anaphylactic Shock and Hypersensitivity Reactions Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening with clinically significant hypotension and shock have occurred in patients receiving Mozobil [see Adverse Reactions (6.2) ] . Observe patients for signs and symptoms of hypersensitivity during and after Mozobil administration for at least 30 minutes and until clinically stable following completion of each administration. Only administer Mozobil when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions. In clinical studies, mild or moderate allergic reactions occurred within approximately 30 minutes after Mozobil administration in less than 1% of patients [see Adverse Reactions (6.1) ] . 5.2 Tumor Cell Mobilization in Leukemia Patients For the purpose of HSC mobilization, Mozobil may cause mobilization of leukemic cells and subsequent contamination of the apheresis product. Therefore, Mozobil is not intended for HSC mobilization and harvest in patients with leukemia. 5.3 Hematologic Effects Leukocytosis Administration of Mozobil in conjunction with filgrastim increases circulating leukocytes as well as HSC populations. Monitor white blood cell counts during Mozobil use [see Adverse Reactions (6.1) ] . Thrombocytopenia Thrombocytopenia has been observed in patients receiving Mozobil. Monitor platelet counts in all patients who receive Mozobil and then undergo apheresis. 5.4 Potential for Tumor Cell Mobilization When Mozobil is used in combination with filgrastim for HSC mobilization‚ tumor cells may be released from the marrow and subsequently collected in the leukapheresis product. The effect of potential reinfusion of tumor cells has not been well-studied. 5.5 Splenic Enlargement and Rupture Higher absolute and relative spleen weights associated with extramedullary hematopoiesis were observed following prolonged (2 to 4 weeks) daily plerixafor SC administration in rats at doses approximately 4-fold higher than the recommended human dose based on body surface area. The effect of Mozobil on spleen size in patients was not specifically evaluated in clinical studies. Cases of splenic enlargement and/or rupture have been reported following the administration of Mozobil in conjunction with filgrastim. Evaluate individuals receiving Mozobil in combination with filgrastim who report left upper abdominal pain and/or scapular or shoulder pain for splenic integrity. 5.6 Embryo-Fetal Toxicity Based on findings from animal reproduction studies, Mozobil can cause fetal harm when administered to a pregnant woman. Plerixafor administration to pregnant rats during organogenesis resulted in embryo-fetal mortality, structural abnormalities, and alterations to growth at exposures approximately 10 times the exposure at the recommended human dose. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use an effective form of contraception during treatment with Mozobil and for one week after the final dose [see Use in Specific Populations (8.1) ] ."],"clinical_studies_table":["
Table 5: Study 1 Efficacy Results - CD34+ Cell Mobilization in NHL Patients
Efficacy EndpointMozobil and Filgrastim (n=150)Placebo and Filgrastim (n=148)p-valuep-value calculated using Pearson's Chi-Squared test
Patients achieving ≥5 × 106 cells/kg in ≤4 apheresis days89 (59%)29 (20%)<0.001
Patients achieving ≥2 × 106 cells/kg in ≤4 apheresis days130 (87%)70 (47%)<0.001
","
Table 6: Study 1 Efficacy Results – Proportion of Patients Who Achieved ≥5 × 106 CD34+ cells/kg by Apheresis Day in NHL Patients
DaysProportionPercents determined by Kaplan Meier method in Mozobil and Filgrastim (n=147n includes all patients who received at least one day of apheresis)Proportion in Placebo and Filgrastim (n=142)
127.9%4.2%
249.1%14.2%
357.7%21.6%
465.6%24.2%
","
Table 7: Study 2 Efficacy Results – CD34+ Cell Mobilization in Multiple Myeloma Patients
Efficacy EndpointMozobil and Filgrastim (n=148)Placebo and Filgrastim (n=154)p-valuep-value calculated using Pearson's Chi-Squared test
Patients achieving ≥6 × 106 cells/kg in ≤2 apheresis days 106 (72%) 53 (34%) <0.001
Patients achieving ≥6 × 106 cells/kg in ≤4 apheresis days 112 (76%)79 (51%)<0.001
Patients achieving ≥2 × 106 cells/kg in ≤4 apheresis days 141 (95%)136 (88%)0.028
","
Table 8: Study 2 – Proportion of Patients Who Achieved ≥6 × 106 CD34+ cells/kg by Apheresis Day in MM Patients
Days ProportionPercents determined by Kaplan Meier methodin Mozobil and Filgrastim (n=144n includes all patients who received at least one day of apheresis) Proportion in Placebo and Filgrastim (n=150)
1 54.2% 17.3%
2 77.9% 35.3%
3 86.8% 48.9%
4 86.8% 55.9%
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies with plerixafor have not been conducted. Plerixafor was not genotoxic in an in vitro bacterial mutation assay (Ames test in Salmonella ), an in vitro chromosomal aberration test using V79 Chinese hamster cells, or an in vivo bone marrow micronucleus test in rats after subcutaneous doses up to 25 mg/kg (150 mg/m 2 ). The effect of plerixafor on human fertility is unknown. The effect of plerixafor on male fertility was not studied in designated reproductive toxicology studies. The staging of spermatogenesis measured in a 28-day repeated dose toxicity study in rats revealed no abnormalities considered to be related to plerixafor. No histopathological evidence of toxicity to male or female reproductive organs was observed in 28-day repeated dose toxicity studies. No adverse effects on estrus or reproductive indices were observed in an investigative fertility study in female rats administered plerixafor at doses up to 90 mg/m 2 (15mg/kg/day) or approximately 10 times the recommended human dose of 0.24 mg/kg when compared on a mg/m 2 basis."],"pharmacodynamics_table":["
Table 3: Fold Increase in Peripheral Blood CD34+ Cell Count Following Pretreatment with Filgrastim and Administration of Plerixafor
StudyMozobil and FilgrastimPlacebo and Filgrastim
Median Mean (SD) Median Mean (SD)
Study 1 5.0 6.1 (5.4) 1.4 1.9 (1.5)
Study 2 4.8 6.4 (6.8) 1.7 2.4 (7.3)
"],"pharmacokinetics_table":["
Table 4: Systemic Exposure (AUC0–10h) Comparisons of Fixed and Weight-Based Regimens
RegimenGeometric Mean AUC
Fixed 20 mg (n=30)3991.2
0.24 mg/kg (n=31)2792.7
Ratio (90% CI)1.43 (1.32,1.54)
"],"adverse_reactions_table":["
Table 2: Adverse Reactions in ≥5% of Non-Hodgkin's Lymphoma and Multiple Myeloma Patients Receiving Mozobil and More Frequent than Placebo during HSC Mobilization and Apheresis
Percent of Patients (%)
Mozobil and Filgrastim (n=301)Placebo and Filgrastim (n=292)
All GradesGrades based on criteria from the World Health Organization (WHO) Grade 3Grade 4All GradesGrade 3Grade 4
Gastrointestinal disorders
Diarrhea 37<101700
Nausea34102200
Vomiting10<10600
Flatulence700300
General disorders and administration site conditions
Injection site reactions34001000
Fatigue27002500
Musculoskeletal and connective tissue disorders
Arthralgia13001200
Nervous system disorders
Headache22<102110
Dizziness1100600
Psychiatric disorders
Insomnia700500
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise patients of the potential for anaphylactic reactions, including signs and symptoms such as urticaria, periorbital swelling, dyspnea, or hypoxia during and following Mozobil injection and to report these symptoms immediately to a healthcare professional [see Adverse Reactions (6.1 , 6.2) ] . Advise patients to contact healthcare professional immediately if they experience left upper abdominal pain and/or scapular or shoulder pain [see Adverse Reactions (6.1 , 6.2) ] . Advise patients to inform a healthcare professional immediately if symptoms of vasovagal reactions such as orthostatic hypotension or syncope occur during or shortly after their Mozobil injection [see Adverse Reactions (6.1) ] . Advise patients who experience itching, rash, or reaction at the site of injection to notify a healthcare professional, as these symptoms have been treated with over-the-counter medications during clinical trials [see Adverse Reactions (6.1) ] . Advise patients that Mozobil may cause gastrointestinal disorders, including diarrhea, nausea, vomiting, flatulence, and abdominal pain. Patients should be told how to manage specific gastrointestinal disorders and to inform their healthcare professional if severe events occur following Mozobil injection [see Adverse Reactions (6.1) ] . Advise females of reproductive potential of the potential risk to a fetus. Advise females to contact their healthcare provider if they become pregnant, or if pregnancy is suspected, during treatment with Mozobil [see Warnings and Precautions (5.6) , Use in Specific Populations (8.1) ] . Advise females and males of reproductive potential to use effective contraceptive methods during Mozobil use and for 1 week following cessation of treatment [see Warnings and Precautions (5.6) , Use in Specific Populations (8.1) ] . Advise women not to breastfeed during treatment with Mozobil and for 1 week following the last dose [ Use in Specific Populations (8.2) ] ."],"spl_unclassified_section":["Genzyme Corporation Cambridge, MA 02141 A SANOFI COMPANY ©2023 Genzyme Corporation. All rights reserved. Mozobil is a registered trademark of Genzyme Corporation."],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Initiate Mozobil treatment after the patient has received filgrastim once daily for 4 days. ( 2.1 ) Repeat Mozobil dose up to 4 consecutive days. ( 2.1 ) Dose based on patient weight Less than or equal to 83 kg: 20 mg dose or select dose based on 0.24 mg/kg actual body weight. ( 2.1 ) greater than 83 kg: select dose based on 0.24 mg/kg actual body weight. ( 2.1 ) Administer by subcutaneous injection approximately 11 hours prior to initiation of apheresis. ( 2.1 ) Renal impairment: If creatinine clearance is ≤50 mL/min, decrease dose by one-third to 0.16 mg/kg. ( 2.3 ) 2.1 Recommended Dosage and Administration Begin treatment with Mozobil after the patient has received filgrastim once daily for 4 days [see Dosage and Administration (2.2) ] . Administer Mozobil approximately 11 hours prior to initiation of each apheresis for up to 4 consecutive days. The recommended dose of Mozobil by subcutaneous injection is based on body weight: 20 mg fixed dose or 0.24 mg/kg of body weight for patients weighing less than or equal to 83 kg. [see Clinical Pharmacology (12.3) ] 0.24 mg/kg of body weight for patients weighing greater than 83 kg Use the patient's actual body weight to calculate the volume of Mozobil to be administered. Each vial delivers 1.2 mL of 20 mg/mL solution, and the volume to be administered to patients should be calculated from the following equation: 0.012 × patient's actual body weight (in kg) = volume to be administered (in mL) In clinical studies, Mozobil dose has been calculated based on actual body weight in patients up to 175% of ideal body weight. Mozobil dose and treatment of patients weighing more than 175% of ideal body weight have not been investigated. Based on increasing exposure with increasing body weight, the Mozobil dose should not exceed 40 mg/day [see Clinical Pharmacology (12.3) ] . Vials should be inspected visually for particulate matter and discoloration prior to administration and should not be used if there is particulate matter or if the solution is discolored. Discard unused portion. 2.2 Recommended Concomitant Medications Administer daily morning doses of filgrastim 10 mcg/kg for 4 days prior to the first evening dose of Mozobil and on each day prior to apheresis [see Clinical Studies (14) ] . 2.3 Dose Modifications in Renal Impairment In patients with moderate and severe renal impairment (estimated creatinine clearance (CL CR ) less than or equal to 50 mL/min), reduce the dose of Mozobil by one-third based on body weight category as shown in Table 1. If CL CR is less than or equal to 50 mL/min the dose should not exceed 27 mg/day, as the mg/kg-based dosage results in increased plerixafor exposure with increasing body weight [see Clinical Pharmacology (12.3) ] . Similar systemic exposure is predicted if the dose is reduced by one-third in patients with moderate and severe renal impairment compared with subjects with normal renal function [see Clinical Pharmacology (12.3) ] . Table 1: Recommended Dosage of Mozobil in Patients with Renal Impairment Estimated Creatinine Clearance (mL/min) Dose Body Weight less than or equal to 83 kg Body Weight greater than 83 kg and less than 160 kg greater than 50 20 mg or 0.24 mg/kg once daily 0.24 mg/kg once daily (not to exceed 40 mg/day) less than or equal to 50 13 mg or 0.16 mg/kg once daily 0.16 mg/kg once daily (not to exceed 27 mg/day) The following (Cockcroft-Gault) formula may be used to estimate CL CR : Males: Creatinine clearance (mL/min) = weight (kg) × (140 – age in years) 72 × serum creatinine (mg/dL) Females: Creatinine clearance (mL/min) = 0.85 × value calculated for males There is insufficient information to make dosage recommendations in patients on hemodialysis."],"spl_product_data_elements":["Mozobil PLERIXAFOR PLERIXAFOR PLERIXAFOR SODIUM CHLORIDE HYDROCHLORIC ACID WATER SODIUM HYDROXIDE"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Injection: 24 mg/1.2 mL (20 mg/mL) sterile, clear, colorless to pale-yellow solution in a single-dose vial. Injection: 24 mg/1.2 mL (20 mg/mL) in a single-dose vial. ( 3 )"],"clinical_pharmacology_table":["
Table 3: Fold Increase in Peripheral Blood CD34+ Cell Count Following Pretreatment with Filgrastim and Administration of Plerixafor
StudyMozobil and FilgrastimPlacebo and Filgrastim
Median Mean (SD) Median Mean (SD)
Study 1 5.0 6.1 (5.4) 1.4 1.9 (1.5)
Study 2 4.8 6.4 (6.8) 1.7 2.4 (7.3)
","
Table 4: Systemic Exposure (AUC0–10h) Comparisons of Fixed and Weight-Based Regimens
RegimenGeometric Mean AUC
Fixed 20 mg (n=30)3991.2
0.24 mg/kg (n=31)2792.7
Ratio (90% CI)1.43 (1.32,1.54)
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary Limited available data with Mozobil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. In animal reproduction studies, subcutaneous administration of plerixafor to pregnant rats during organogenesis at doses 10-times the maximum recommended human doses resulted in embryo-fetal mortality, structural abnormalities, and alterations to growth [see Data ] . Advise pregnant women of the potential risk to the fetus. Advise women of reproductive potential to avoid becoming pregnant while receiving treatment with Mozobil [see Warnings and Precautions (5.6) ]. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriages for the indicated population is unknown. Data Animal data Plerixafor administered to pregnant rats induced embryo-fetal toxicity, including fetal death, increased resorptions and postimplantation loss, decreased fetal weights, anophthalmia, shortened digits, cardiac interventricular septal defect, ringed aorta, globular heart, hydrocephaly, dilatation of olfactory ventricles, and retarded skeletal development. Embryo-fetal toxicities occurred mainly at a dose of 90 mg/m 2 (approximately 10 times the recommended human dose of 0.24 mg/kg when compared on a mg/m 2 basis). 8.2 Lactation Risk Summary There are no data on the presence of plerixafor in human milk, the effect on the breastfed child, or the effect on milk production. Because of the potential serious adverse reactions in the breastfed child, advise females that breastfeeding is not recommended during treatment with Mozobil and for one week after the final dose. 8.3 Females and Males of Reproductive Potential Pregnancy Testing Verify pregnancy status in females of reproductive potential prior to initiating Mozobil [see Use in Specific Populations (8.1) ] . Contraception Females Mozobil can cause embryo-fetal harm when administered to pregnant women [see Use in Specific Populations (8.1) ] . Advise females of reproductive potential to use effective contraception during treatment with Mozobil and for one week after the final dose. Males Males treated with Mozobil should use effective contraception during treatment and for one week after cessation of treatment. 8.4 Pediatric Use The safety and effectiveness of Mozobil have not been established in pediatric patients. Effectiveness was not demonstrated in a single phase 1/2 randomized, open-label, comparative study of Mozobil plus standard regimens for mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Forty-five pediatric patients ages 1 to <17 years with solid tumors or lymphoma were randomized 2:1 to Mozobil in addition to standard mobilization regimens (N=30) or standard mobilization regimens alone (N=15) (comparator arm). No new safety signals were observed in pediatric patients in this trial. The day prior to the first apheresis, median peripheral blood CD34+ counts were 35 × 10 6 cells/L in the comparator arm and 15 × 10 6 cells/L in the Mozobil arm. On the day of the first apheresis, median peripheral blood CD34+ counts were 64 × 10 6 cells/L in the comparator arm and 77 × 10 6 cells/L in the Mozobil arm. Plerixafor exposure, shown as AUC, in pediatric patients aged 12 to 18 years was within the range of values previously observed in adults, while the AUC of plerixafor in pediatric patients aged 2 to 12 years was 67% to 87% of that observed in adults, given the same adult dose (0.24 mg/kg). 8.5 Geriatric Use Of the total number of subjects in controlled clinical studies of Mozobil, 24% were 65 and over, while 0.8% were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Since plerixafor is mainly excreted by the kidney, no dose modifications are necessary in elderly individuals with normal renal function. In general, care should be taken in dose selection for elderly patients due to the greater frequency of decreased renal function with advanced age. Dosage adjustment in elderly patients with CL CR less than or equal to 50 mL/min is recommended [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . 8.6 Renal Impairment In patients with moderate and severe renal impairment (CL CR less than or equal to 50 mL/min), reduce the dose of Mozobil by one-third to 0.16 mg/kg [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] ."],"dosage_and_administration_table":["
Table 1: Recommended Dosage of Mozobil in Patients with Renal Impairment
Estimated Creatinine Clearance (mL/min)Dose
Body Weight less than or equal to 83 kgBody Weight greater than 83 kg and less than 160 kg
greater than 5020 mg or 0.24 mg/kg once daily0.24 mg/kg once daily (not to exceed 40 mg/day)
less than or equal to 5013 mg or 0.16 mg/kg once daily0.16 mg/kg once daily (not to exceed 27 mg/day)
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 24 mg/1.2 mL Vial Carton NDC 0024-5862-01 Mozobil ® (plerixafor) injection 24 mg/1.2 mL (20 mg/mL) For subcutaneous injection only One single-dose vial. Discard unused portion. Rx only SANOFI GENZYME PRINCIPAL DISPLAY PANEL - 24 mg/1.2 mL Vial Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies with plerixafor have not been conducted. Plerixafor was not genotoxic in an in vitro bacterial mutation assay (Ames test in Salmonella ), an in vitro chromosomal aberration test using V79 Chinese hamster cells, or an in vivo bone marrow micronucleus test in rats after subcutaneous doses up to 25 mg/kg (150 mg/m 2 ). The effect of plerixafor on human fertility is unknown. The effect of plerixafor on male fertility was not studied in designated reproductive toxicology studies. The staging of spermatogenesis measured in a 28-day repeated dose toxicity study in rats revealed no abnormalities considered to be related to plerixafor. No histopathological evidence of toxicity to male or female reproductive organs was observed in 28-day repeated dose toxicity studies. No adverse effects on estrus or reproductive indices were observed in an investigative fertility study in female rats administered plerixafor at doses up to 90 mg/m 2 (15mg/kg/day) or approximately 10 times the recommended human dose of 0.24 mg/kg when compared on a mg/m 2 basis."]},"tags":[{"label":"Hematopoietic Stem Cell Mobilizer","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"C-C chemokine receptor type 2","category":"target"},{"label":"CCR2","category":"gene"},{"label":"ACKR3","category":"gene"},{"label":"CCR4","category":"gene"},{"label":"L03AX16","category":"atc"},{"label":"Subcutaneous","category":"route"},{"label":"Injection","category":"form"},{"label":"Solution","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Malignant lymphoma","category":"indication"},{"label":"Multiple myeloma","category":"indication"},{"label":"Peripheral Mobilization of Hematopoietic Stem Cells","category":"indication"},{"label":"Solid malignant tumours","category":"indication"},{"label":"Genzyme","category":"company"},{"label":"Approved 2000s","category":"decade"},{"label":"Anti-HIV Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Anti-Retroviral Agents","category":"pharmacology"},{"label":"Antiviral Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"FEBRILE NEUTROPENIA","source":"FDA FAERS","actionTaken":"140 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"119 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"100 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"84 reports"},{"date":"","signal":"MUCOSAL INFLAMMATION","source":"FDA FAERS","actionTaken":"83 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"80 reports"},{"date":"","signal":"THROMBOCYTOPENIA","source":"FDA FAERS","actionTaken":"78 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"61 reports"},{"date":"","signal":"PLASMA CELL MYELOMA","source":"FDA FAERS","actionTaken":"60 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"55 reports"}],"commonSideEffects":[{"effect":"Diarrhea","drugRate":"37%","severity":"common","_validated":true},{"effect":"Nausea","drugRate":"34%","severity":"common","_validated":true},{"effect":"Fatigue","drugRate":"27%","severity":"common","_validated":true},{"effect":"Injection site reactions","drugRate":"24%","severity":"common","_validated":true},{"effect":"Headache","drugRate":"22%","severity":"common","_validated":true},{"effect":"Arthralgia","drugRate":"13%","severity":"mild","_validated":true},{"effect":"Dizziness","drugRate":"11%","severity":"mild","_validated":true},{"effect":"Vomiting","drugRate":"10%","severity":"mild","_validated":true},{"effect":"Flatulence","drugRate":"7%","severity":"mild","_validated":true},{"effect":"Hyperleukocytosis","drugRate":"7%","severity":"serious","_validated":true},{"effect":"Gastrointestinal disorders","drugRate":"6%","severity":"mild","_validated":true},{"effect":"General disorders and administration site conditions","drugRate":"5%","severity":"mild","_validated":true},{"effect":"Musculoskeletal and connective tissue disorders","drugRate":"5%","severity":"mild","_validated":true},{"effect":"Nervous system disorders","drugRate":"5%","severity":"mild","_validated":true},{"effect":"Psychiatric disorders","drugRate":"5%","severity":"mild","_validated":true},{"effect":"Abdominal pain","drugRate":"<5%","severity":"mild","_validated":true},{"effect":"Hyperhidrosis","drugRate":"<5%","severity":"mild","_validated":true},{"effect":"Abdominal distention","drugRate":"<5%","severity":"mild","_validated":true},{"effect":"Dry mouth","drugRate":"<5%","severity":"mild","_validated":true},{"effect":"Erythema","drugRate":"<5%","severity":"mild","_validated":true},{"effect":"Stomach discomfort","drugRate":"<5%","severity":"mild","_validated":true},{"effect":"Malaise","drugRate":"<5%","severity":"mild","_validated":true},{"effect":"Hypoesthesia oral","drugRate":"<5%","severity":"mild","_validated":true},{"effect":"Constipation","drugRate":"<5%","severity":"mild","_validated":true},{"effect":"Dyspepsia","drugRate":"<5%","severity":"mild","_validated":true},{"effect":"Musculoskeletal pain","drugRate":"<5%","severity":"mild","_validated":true},{"effect":"Splenomegaly","drugRate":"<5%","severity":"serious","_validated":true},{"effect":"Splenic rupture","drugRate":"<5%","severity":"serious","_validated":true},{"effect":"Anaphylactic reactions","drugRate":"<5%","severity":"serious","_validated":true},{"effect":"Anaphylactic shock","drugRate":"<5%","severity":"serious","_validated":true}],"contraindications":["Breastfeeding (mother)","Impaired renal function disorder","Leukemia, disease","Leukocytosis","Nontraumatic splenic rupture","Pregnancy, function","Thrombocytopenic disorder"],"specialPopulations":{"Lactation":"There are no data on the presence of plerixafor in human milk, the effect on the breastfed child, or the effect on milk production. Because of the potential serious adverse reactions in the breastfed child, advise females that breastfeeding is not recommended during treatment with plerixafor and for one week after the final dose.","Pregnancy":"Limited available data with plerixafor use in pregnant women are insufficient to inform drug-associated risk of adverse developmental outcomes. In animal reproduction studies, subcutaneous administration of plerixafor to pregnant rats during organogenesis at doses 10-times the maximum recommended human doses resulted in embryo-fetal mortality, structural abnormalities, and alterations to growth. Advise pregnant women of the potential risk to the fetus. Advise women of reproductive potential to avoid becoming pregnant while receiving treatment with plerixafor.","Geriatric use":"Of the total number of subjects in controlled clinical studies of plerixafor, 24% were 65 and over, while 0.8% were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.","Paediatric use":"The safety and effectiveness of plerixafor injection have not been established in pediatric patients. Effectiveness was not demonstrated in single phase 1/2 randomized, open-label, comparative study of plerixafor injection plus standard regimens for mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation."}},"trials":[],"aliases":[],"company":"Sanofi","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=plerixafor","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:52:16.703461+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Plerixafor","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:52:25.607368+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:52:23.774485+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:52:16.771396+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:52:12.491609+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:52:11.572307+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:52:11.572343+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:52:11.572349+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:52:26.022988+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5402188/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:52:25.257327+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA022311","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:52:11.572352+00:00"}},"allNames":"mozobil","offLabel":[],"synonyms":["plerixafor hydrochloride","plerixafor HCl","AMD3100","AMD 3100","plerixafor","mozobil"],"timeline":[{"date":"2008-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from GENZYME to Genzyme"},{"date":"2008-12-15","type":"positive","source":"DrugCentral","milestone":"FDA approval (Genzyme)"},{"date":"2009-07-30","type":"positive","source":"DrugCentral","milestone":"EMA approval (Sanofi B.V.)"},{"date":"2023-07-24","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 7 manufacturers approved"}],"brandName":"Mozobil","ecosystem":[{"indication":"Malignant lymphoma","otherDrugs":[{"name":"busulfan","slug":"busulfan","company":"Aspen Global"},{"name":"cyclophosphamide","slug":"cyclophosphamide","company":"Baxter Hlthcare"},{"name":"thiotepa","slug":"thiotepa","company":""}],"globalPrevalence":null},{"indication":"Multiple myeloma","otherDrugs":[{"name":"belantamab mafodotin","slug":"belantamab-mafodotin","company":"Glaxosmithkline"},{"name":"bortezomib","slug":"bortezomib","company":"Millennium Pharms"},{"name":"carfilzomib","slug":"carfilzomib","company":"Onyx Pharms"},{"name":"carmustine","slug":"carmustine","company":"Emcure Pharms Ltd"}],"globalPrevalence":176000},{"indication":"Peripheral Mobilization of Hematopoietic Stem Cells","otherDrugs":[],"globalPrevalence":null},{"indication":"Solid malignant tumours","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"C-C chemokine receptor type 2","novelty":"Follow-on","targets":[{"gene":"CCR2","source":"DrugCentral","target":"C-C chemokine receptor type 2","protein":"C-C chemokine receptor type 2"},{"gene":"ACKR3","source":"DrugCentral","target":"Atypical chemokine receptor 3","protein":"Atypical chemokine receptor 3"},{"gene":"CCR4","source":"DrugCentral","target":"C-C chemokine receptor type 4","protein":"C-C chemokine receptor type 4"},{"gene":"CXCR4","source":"DrugCentral","target":"C-X-C chemokine receptor type 4","protein":"C-X-C chemokine receptor type 4"},{"gene":"CXCL12","source":"DrugCentral","target":"Stromal cell-derived factor 1","protein":"Stromal cell-derived factor 1"}],"modality":"Small Molecule","drugClass":"Hematopoietic Stem Cell Mobilizer [EPC]","explanation":"Plerixafor is an inhibitor of the CXCR4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1 (SDF-1). SDF-1 and CXCR4 are recognized to play role in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrow compartment. Once in the marrow, stem cell CXCR4 can act to help anchor these cells to the marrow matrix, either directly via SDF-1 or through the induction of other adhesion molecules. Treatment with plerixafor resulted in leukocytosis and elevations in circulating hematopoietic progenitor cells in mice, dogs and humans. CD34+ cells mobilized by plerixafor were capable of engraftment with long-term repopulating capacity up to one year in canine transplantation models.","oneSentence":"Mozobil works by binding to the C-C chemokine receptor type 2, which helps to mobilize hematopoietic stem cells from the bone marrow into the bloodstream.","technicalDetail":"Mozobil (plerixafor) is a CXCR4 antagonist that selectively binds to the C-C chemokine receptor type 2 (CXCR4) on the surface of hematopoietic stem cells, inducing a conformational change that disrupts the interaction between CXCR4 and its ligand, stromal cell-derived factor-1 (SDF-1), thereby promoting the mobilization of stem cells from the bone marrow into the bloodstream."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Plerixafor","title":"Plerixafor","extract":"Plerixafor, sold under the brand name Mozobil, is an immunostimulant used to mobilize hematopoietic stem cells in cancer patients into the bloodstream. The stem cells are then extracted from the blood and transplanted back to the patient. The drug was developed by AnorMED, which was subsequently bought by Genzyme.","wiki_history":"==History==\nThe molecule was first synthesised in 1987 to carry out basic studies on the redox chemistry of dimetallic coordination compounds. Then, it was serendipitously discovered by another chemist that such a molecule could have a potential use in the treatment of HIV because of its role in the blocking of CXCR4, a chemokine receptor which acts as a co-receptor for certain strains of HIV (along with the virus's main cellular receptor, CD4). Development of this indication was terminated because of lacking oral availability and cardiac disturbances. Further studies led to the new indication for cancer patients.","wiki_society_and_culture":"==Society and culture==\nPlerixafor has orphan drug status in the United States and European Union for the mobilization of hematopoietic stem cells. It was approved by the U.S. Food and Drug Administration (FDA) for this indication on 15 December 2008. In the European Union, the drug was approved after a positive Committee for Medicinal Products for Human Use assessment report on 29 May 2009."},"commercial":{"launchDate":"2008","_launchSource":"DrugCentral (FDA 2008-12-15, GENZYME)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4410","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=plerixafor","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=plerixafor","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Plerixafor","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T02:32:15.859005","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:52:28.520469+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"pegademase","drugSlug":"pegademase","fdaApproval":"1990-03-21","relationship":"same-class"},{"drugName":"glatiramer acetate","drugSlug":"glatiramer-acetate","fdaApproval":"1996-12-20","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"histamine","drugSlug":"histamine","fdaApproval":"1939-04-25","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"elapegademase","drugSlug":"elapegademase","fdaApproval":"2018-10-05","relationship":"same-class"}],"genericName":"plerixafor","indications":{"approved":[{"name":"Malignant lymphoma","source":"DrugCentral","snomedId":118600007,"regulator":"FDA","eligibility":"patients with non-Hodgkins lymphoma (NHL)"},{"name":"Multiple myeloma","source":"DrugCentral","snomedId":109989006,"regulator":"FDA","eligibility":"patients with multiple myeloma (MM)","usPrevalence":35000,"globalPrevalence":176000,"prevalenceMethod":"curated","prevalenceSource":"IARC GLOBOCAN, 2022"},{"name":"Peripheral Mobilization of Hematopoietic Stem Cells","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"patients with non-Hodgkins lymphoma (NHL) or multiple myeloma"},{"name":"Solid malignant tumours","source":"DrugCentral","snomedId":81920005,"regulator":"FDA","eligibility":"Not specified"}],"offLabel":[],"pipeline":[]},"currentOwner":"Genzyme","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"pegademase","brandName":"pegademase","genericName":"pegademase","approvalYear":"1990","relationship":"same-class"},{"drugId":"glatiramer-acetate","brandName":"glatiramer acetate","genericName":"glatiramer acetate","approvalYear":"1996","relationship":"same-class"},{"drugId":"histamine","brandName":"histamine","genericName":"histamine","approvalYear":"1939","relationship":"same-class"},{"drugId":"elapegademase","brandName":"elapegademase","genericName":"elapegademase","approvalYear":"2018","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00103662","phase":"PHASE3","title":"Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":true,"startDate":"2005-01","conditions":["Multiple Myeloma"],"enrollment":302,"completionDate":"2008-01"},{"nctId":"NCT00103610","phase":"PHASE3","title":"Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":true,"startDate":"2005-01","conditions":["Lymphoma, Non-Hodgkin"],"enrollment":298,"completionDate":"2007-12"},{"nctId":"NCT00967785","phase":"PHASE1,PHASE2","title":"A Phase I Study of Mozobil in the Treatment of Patients With WHIMS","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-01-06","conditions":["Leukopenia","Neutropenia","Infections","Warts","Myelokathexis"],"enrollment":20,"completionDate":"2026-12-31"},{"nctId":"NCT02015013","phase":"PHASE2","title":"Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-01-15","conditions":["Idiopathic CD4-Positive","T-Lymphocytopenia"],"enrollment":40,"completionDate":"2026-10-31"},{"nctId":"NCT06325709","phase":"PHASE1,PHASE2","title":"Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-04-17","conditions":["Chronic Granulomatous Disease (CGD)","X-Linked Chronic Granulomatous Disease"],"enrollment":10,"completionDate":"2032-12-31"},{"nctId":"NCT05357482","phase":"PHASE1,PHASE2","title":"Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-05-12","conditions":["Sickle Cell Anemia","Beta Thalassemia"],"enrollment":40,"completionDate":"2027-01-31"},{"nctId":"NCT05470491","phase":"PHASE1,PHASE2","title":"Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-01-26","conditions":["HIV","Hematologic Malignancies"],"enrollment":265,"completionDate":"2027-07-30"},{"nctId":"NCT07423728","phase":"NA","title":"CHRONO-MOBILIZE: Chronotherapy of G-CSF for CD34+ Mobilization in Healthy Donors","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2026-03-01","conditions":["Granulocyte Colony-Stimulating Factor (G-CSF) Mobilization"],"enrollment":160,"completionDate":"2027-03-30"},{"nctId":"NCT06207799","phase":"PHASE2","title":"Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-07-17","conditions":["Multiple Myeloma","Post-transplant MRD-guided Maintenance Therapy","Pre-transplant Purging"],"enrollment":40,"completionDate":"2031-12-31"},{"nctId":"NCT06851767","phase":"PHASE1,PHASE2","title":"Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-05-09","conditions":["X-linked Severe Combined Immunodeficiency","X-SCID","XSCID"],"enrollment":18,"completionDate":"2034-12-31"},{"nctId":"NCT06158828","phase":"PHASE1,PHASE2","title":"Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-15","conditions":["AML, Childhood","Aml","Acute Myeloid Leukemia, Pediatric","Acute Myeloid Leukemia"],"enrollment":68,"completionDate":"2030-05-31"},{"nctId":"NCT07341022","phase":"PHASE1,PHASE2","title":"STEM CELL MOBILIZATION WITH HIGH-DOSE PLERIXAFOR IN PATIENTS WITH SICKLE CELL DISEASE","status":"NOT_YET_RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2026-06-01","conditions":["Sickle Cell Disease"],"enrollment":12,"completionDate":"2028-06"},{"nctId":"NCT06414889","phase":"PHASE1","title":"Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-05-20","conditions":["RUNX1 Familial Platelet Disorder"],"enrollment":4,"completionDate":"2027-06-30"},{"nctId":"NCT05088356","phase":"PHASE1","title":"Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-09-07","conditions":["Allogeneic Hematopoietic Cell Transplantation (HCT)","Advanced Hematologic Malignancies","Acute Leukemia","Chronic Myelogenous Leukemia","Myelodysplastic Syndromes","Myeloproliferative Disorders"],"enrollment":60,"completionDate":"2027-11"},{"nctId":"NCT03317899","phase":"PHASE2","title":"Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2017-10-12","conditions":["Non-Hodgkin's Lymphoma","Plasma Cell Myeloma"],"enrollment":77,"completionDate":"2022-11-16"},{"nctId":"NCT05456880","phase":"PHASE1,PHASE2","title":"BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beam Therapeutics Inc.","startDate":"2022-08-30","conditions":["Sickle Cell Disease"],"enrollment":15,"completionDate":"2028-02"},{"nctId":"NCT07188090","phase":"PHASE2","title":"Mozobil for Autologous Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2025-10-16","conditions":["Multiple Myeloma","Hodgkin Lymphoma","Non-hodgkin Lymphoma"],"enrollment":100,"completionDate":"2028-06"},{"nctId":"NCT02570542","phase":"PHASE2","title":"Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2015-10","conditions":["Diffuse Large B-cell Lymphoma (DLBCL)","Relapsed Diffuse Large B-cell Lymphoma (DLBCL)","Refractory Diffuse Large B-cell Lymphoma (DLBCL)"],"enrollment":59,"completionDate":"2026-10"},{"nctId":"NCT03746080","phase":"PHASE2","title":"Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma","status":"COMPLETED","sponsor":"Lawrence D Recht","startDate":"2018-12-04","conditions":["Glioblastoma","Glioblastoma With Primitive Neuronal Component","Gliosarcoma","Malignant Glioma","Oligodendroglial Component Present"],"enrollment":21,"completionDate":"2024-02-08"},{"nctId":"NCT06506461","phase":"PHASE1","title":"Gene Editing For Sickle Cell Disease","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-03-21","conditions":["Sickle Cell Disease"],"enrollment":25,"completionDate":"2032-12"},{"nctId":"NCT05343572","phase":"EARLY_PHASE1","title":"Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium","status":"RECRUITING","sponsor":"Hugh Taylor","startDate":"2023-11-01","conditions":["Asherman Syndrome","Atrophic Endometrium","Recurrent Implantation Failure"],"enrollment":90,"completionDate":"2027-12"},{"nctId":"NCT01526096","phase":"PHASE1","title":"Stem Cell Transplantation for Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2011-07-12","conditions":["Myeloma"],"enrollment":30,"completionDate":"2024-08-28"},{"nctId":"NCT01815749","phase":"PHASE1","title":"Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2013-10-08","conditions":["Adult Grade III Lymphomatoid Granulomatosis","Cutaneous B-cell Non-Hodgkin Lymphoma","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Intraocular Lymphoma","Nodal Marginal Zone B-cell Lymphoma","Post-transplant Lymphoproliferative Disorder","Recurrent Adult Burkitt Lymphoma","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Adult Diffuse Mixed Cell Lymphoma","Recurrent Adult Diffuse Small Cleaved Cell Lymphoma","Recurrent Adult Grade III Lymphomatoid Granulomatosis","Recurrent Adult Immunoblastic Large Cell Lymphoma","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent Small Lymphocytic Lymphoma","Refractory Hairy Cell Leukemia","Small Intestine Lymphoma","Splenic Marginal Zone Lymphoma","Testicular Lymphoma","Waldenström Macroglobulinemia"],"enrollment":30,"completionDate":"2026-06-01"},{"nctId":"NCT05087212","phase":"PHASE4","title":"Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-10-22","conditions":["Autologous Haematopoietic Stem Cell Transplant"],"enrollment":53,"completionDate":"2022-12-30"},{"nctId":"NCT07186179","phase":"","title":"Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2025-10-01","conditions":["Diamond Blackfan Anemia"],"enrollment":10,"completionDate":"2027-04-01"},{"nctId":"NCT03055247","phase":"PHASE2","title":"Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2015-11-06","conditions":["Chronic Granulomatous Disease X-linked (X-CGD)"],"enrollment":3,"completionDate":"2026-07-18"},{"nctId":"NCT03664830","phase":"PHASE1","title":"Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2018-09-19","conditions":["Sickle Cell Disease"],"enrollment":5,"completionDate":"2026-08-03"},{"nctId":"NCT03653247","phase":"PHASE1,PHASE2","title":"A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease","status":"COMPLETED","sponsor":"Sangamo Therapeutics","startDate":"2019-03-06","conditions":["Sickle Cell Disease"],"enrollment":7,"completionDate":"2025-07-17"},{"nctId":"NCT02678533","phase":"PHASE1,PHASE2","title":"Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-02-10","conditions":["Fanconi Anemia"],"enrollment":4,"completionDate":"2019-05-03"},{"nctId":"NCT02212535","phase":"PHASE1,PHASE2","title":"Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-01-15","conditions":["Major Sickle Cell Syndrome of Type SS or Sβ Thalassemia"],"enrollment":3,"completionDate":"2017-09-27"},{"nctId":"NCT04362293","phase":"PHASE2","title":"Reduced Intensity Transplantation for Severe Sickle Cell Disease","status":"SUSPENDED","sponsor":"St. Jude Children's Research Hospital","startDate":"2020-04-30","conditions":["Sickle Cell Disease"],"enrollment":40,"completionDate":"2029-08-01"},{"nctId":"NCT05445128","phase":"PHASE2","title":"Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease","status":"TERMINATED","sponsor":"Ensoma","startDate":"2022-06-24","conditions":["Sickle Cell Disease"],"enrollment":1,"completionDate":"2023-02-02"},{"nctId":"NCT04548843","phase":"PHASE1","title":"A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion","status":"WITHDRAWN","sponsor":"Minovia Therapeutics Ltd.","startDate":"2022-03-01","conditions":["Primary Mitochondrial Diseases"],"enrollment":0,"completionDate":"2024-12-01"},{"nctId":"NCT01318317","phase":"PHASE1,PHASE2","title":"Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2011-09-19","conditions":["Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Non-Hodgkin Lymphoma"],"enrollment":8,"completionDate":"2026-02-26"},{"nctId":"NCT02193191","phase":"PHASE1","title":"Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-09-17","conditions":["Sickle Cell Disease"],"enrollment":25,"completionDate":"2025-03-27"},{"nctId":"NCT06892119","phase":"PHASE1","title":"Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2019-12-09","conditions":["Lymphoma","Myeloma"],"enrollment":6,"completionDate":"2020-11-30"},{"nctId":"NCT01186224","phase":"NA","title":"Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2010-05","conditions":["Multiple Myeloma","Plasma Cell Dyscrasia","Lymphoma","Lymphoproliferative Disorders"],"enrollment":60,"completionDate":"2015-06"},{"nctId":"NCT02140554","phase":"PHASE1,PHASE2","title":"A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease","status":"COMPLETED","sponsor":"Genetix Biotherapeutics Inc.","startDate":"2015-02-02","conditions":["Sickle Cell Disease"],"enrollment":54,"completionDate":"2024-01-30"},{"nctId":"NCT01413100","phase":"PHASE2","title":"Scleroderma Treatment With Autologous Transplant (STAT) Study","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2011-09-15","conditions":["Systemic Scleroderma"],"enrollment":21,"completionDate":"2024-09-11"},{"nctId":"NCT04293185","phase":"PHASE3","title":"A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genetix Biotherapeutics Inc.","startDate":"2020-02-14","conditions":["Sickle Cell Disease"],"enrollment":35,"completionDate":"2027-11"},{"nctId":"NCT04762875","phase":"PHASE2","title":"MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies","status":"TERMINATED","sponsor":"Ensoma","startDate":"2021-06-16","conditions":["Related Donors Donating PBSC to a Family Member","Healthy Donors","Acute Myelogenous Leukemia","Acute Lymphoblastic Leukemia","Myelodysplastic Syndrome"],"enrollment":7,"completionDate":"2022-03-14"},{"nctId":"NCT06399107","phase":"PHASE1,PHASE2","title":"Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease","status":"RECRUITING","sponsor":"Essen Biotech","startDate":"2024-08-01","conditions":["Sickle Cell Disease","Sickle-Cell Disease With Crisis"],"enrollment":85,"completionDate":"2025-12-28"},{"nctId":"NCT06574126","phase":"PHASE2","title":"Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma","status":"RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2024-09-30","conditions":["High Risk Smoldering Multiple Myeloma"],"enrollment":20,"completionDate":"2032-09-30"},{"nctId":"NCT03182426","phase":"PHASE1,PHASE2","title":"Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2017-08-15","conditions":["Diabetes Mellitus, Type 1"],"enrollment":22,"completionDate":"2024-07-15"},{"nctId":"NCT01331018","phase":"PHASE1","title":"Gene Therapy for Fanconi Anemia","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2012-02-22","conditions":["Fanconi Anemia"],"enrollment":3,"completionDate":"2024-02-15"},{"nctId":"NCT02186418","phase":"PHASE1,PHASE2","title":"Gene Transfer for Patients With Sickle Cell Disease","status":"TERMINATED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2014-07","conditions":["Anemia, Sickle Cell"],"enrollment":7,"completionDate":"2022-10-31"},{"nctId":"NCT03157804","phase":"PHASE1,PHASE2","title":"Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A","status":"COMPLETED","sponsor":"Hospital Infantil Universitario Niño Jesús, Madrid, Spain","startDate":"2016-01-07","conditions":["Fanconi Anemia"],"enrollment":9,"completionDate":"2023-09-08"},{"nctId":"NCT04177810","phase":"PHASE2","title":"Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-11-16","conditions":["Metastatic Pancreatic Cancer"],"enrollment":25,"completionDate":"2023-05-19"},{"nctId":"NCT04418414","phase":"PHASE1","title":"Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A","status":"NOT_YET_RECRUITING","sponsor":"Expression Therapeutics, LLC","startDate":"2024-09-01","conditions":["Hemophilia A"],"enrollment":7,"completionDate":"2039-08"},{"nctId":"NCT03406091","phase":"","title":"Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2015-11-26","conditions":["Multiple Myeloma"],"enrollment":300,"completionDate":"2024-01-17"},{"nctId":"NCT03932864","phase":"PHASE1","title":"Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor","status":"COMPLETED","sponsor":"Ensoma","startDate":"2019-04-22","conditions":["Healthy Volunteers"],"enrollment":107,"completionDate":"2020-02-25"},{"nctId":"NCT06141304","phase":"PHASE2","title":"Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2023-09-01","conditions":["Relapsed Adult ALL","Relapsed Adult AML"],"enrollment":28,"completionDate":"2025-07"},{"nctId":"NCT03240861","phase":"PHASE1","title":"Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer","status":"TERMINATED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2017-07-26","conditions":["HLA-A*0201 Positive Cells Present","Locally Advanced Malignant Neoplasm","NY-ESO-1 Positive","Unresectable Malignant Neoplasm","Sarcoma"],"enrollment":5,"completionDate":"2023-10-19"},{"nctId":"NCT03226691","phase":"PHASE1","title":"Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2017-07-25","conditions":["Sickle Cell Disease"],"enrollment":15,"completionDate":"2019-02-27"},{"nctId":"NCT01696461","phase":"PHASE2","title":"A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor","status":"COMPLETED","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2013-05","conditions":["Related Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member","Acute Myelogenous Leukemia","Acute Lymphoblastic Leukemia","Myelodysplastic Syndrome","Chronic Myelogenous Leukemia","Non-Hodgkin's Lymphoma","Hodgkin's Disease","Chronic Lymphocytic Leukemia"],"enrollment":127,"completionDate":"2016-08"},{"nctId":"NCT05411575","phase":"PHASE2","title":"Plerixafor in Acute Respiratory Distress Syndrome Related to COVID-19 (Phase IIb)","status":"WITHDRAWN","sponsor":"4Living Biotech","startDate":"2022-07-19","conditions":["COVID-19 Acute Respiratory Distress Syndrome","COVID-19"],"enrollment":0,"completionDate":"2022-10"},{"nctId":"NCT04817345","phase":"PHASE2","title":"Peripheral Blood Stem Cell Collection From Patients With Sickle Cell Disease (SCD) Using Plerixafor","status":"WITHDRAWN","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-04","conditions":["Sickle Cell Disease"],"enrollment":0,"completionDate":"2023-04"},{"nctId":"NCT02231879","phase":"PHASE2,PHASE3","title":"Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-10-14","conditions":["Myelokathexis","Infections","Neutropenia","Warts","Hypogammaglobulinemia"],"enrollment":20,"completionDate":"2021-02-24"},{"nctId":"NCT03200626","phase":"","title":"Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-06-01","conditions":["Multiple Myeloma","Bone Marrow Transplant Complications"],"enrollment":750,"completionDate":"2022-10-31"},{"nctId":"NCT05510544","phase":"PHASE4","title":"Plerixafor for Poorly Mobilized Lymphoma","status":"UNKNOWN","sponsor":"Peking University","startDate":"2022-12-19","conditions":["Lymphoma"],"enrollment":140,"completionDate":"2024-01-31"},{"nctId":"NCT05007652","phase":"PHASE2","title":"A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2021-09-01","conditions":["Multiple Myeloma and Malignant Lymphoma"],"enrollment":64,"completionDate":"2022-10-25"},{"nctId":"NCT01746173","phase":"PHASE2","title":"CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-07","conditions":["T-cell Non-Hodgkin Lymphoma"],"enrollment":5,"completionDate":"2014-10"},{"nctId":"NCT03612466","phase":"PHASE1","title":"A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy","status":"WITHDRAWN","sponsor":"Albert Einstein College of Medicine","startDate":"2022-08","conditions":["Osteosarcoma","Bone Metastases"],"enrollment":0,"completionDate":"2024-09"},{"nctId":"NCT04552743","phase":"PHASE2","title":"MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma","status":"COMPLETED","sponsor":"Surbhi Sidana, MD","startDate":"2020-10-05","conditions":["Multiple Myeloma"],"enrollment":25,"completionDate":"2022-06-30"},{"nctId":"NCT00669669","phase":"PHASE1,PHASE2","title":"O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-02-25","conditions":["Glioblastoma","Gliosarcoma"],"enrollment":12,"completionDate":"2021-01-20"},{"nctId":"NCT01123499","phase":"","title":"Collection of Peripheral Blood Stem Cells Using G-CSF and Plerixafor in Normal Volunteers","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-06","conditions":["Normal Physiology"],"enrollment":5,"completionDate":"2022-04-28"},{"nctId":"NCT00082329","phase":"PHASE2","title":"G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2004-06-18","conditions":["Healthy"],"enrollment":9,"completionDate":"2012-10-25"},{"nctId":"NCT02703779","phase":"PHASE2","title":"Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)","status":"COMPLETED","sponsor":"Siddhartha Ganguly","startDate":"2016-03","conditions":["Multiple Myeloma"],"enrollment":101,"completionDate":"2020-04-08"},{"nctId":"NCT04091737","phase":"PHASE1","title":"CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease","status":"TERMINATED","sponsor":"CSL Behring","startDate":"2019-10-02","conditions":["Anemia, Sickle Cell"],"enrollment":1,"completionDate":"2021-05-05"},{"nctId":"NCT04045821","phase":"NA","title":"Endometrial Rejuvenation Study","status":"TERMINATED","sponsor":"Reproductive Medicine Associates of New Jersey","startDate":"2020-01-17","conditions":["Infertility of Uterine Origin"],"enrollment":3,"completionDate":"2021-05-04"},{"nctId":"NCT01753453","phase":"PHASE2","title":"An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":["Multiple Myeloma"],"enrollment":23,"completionDate":"2016-09"},{"nctId":"NCT02439476","phase":"","title":"Non-interventional Study on Salvage Auto in Relapsed Myeloma","status":"COMPLETED","sponsor":"Association for Training, Education, and Research in Hematology, Immunology, and Transplantation","startDate":"2016-08-08","conditions":["Relapsed Multiple Myeloma"],"enrollment":23,"completionDate":"2020-08-08"},{"nctId":"NCT04000698","phase":"PHASE3","title":"Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2019-10-15","conditions":["Refractory Acute Myeloid Leukemia","Refractory Acute Lymphoblastic Leukemia"],"enrollment":25,"completionDate":"2022-12"},{"nctId":"NCT00479115","phase":"PHASE1,PHASE2","title":"Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2007-05","conditions":["Fanconi Anemia"],"enrollment":1,"completionDate":"2010-12"},{"nctId":"NCT02750254","phase":"PHASE1","title":"Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2016-06-27","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndrome","Acute Lymphocytic Leukemia"],"enrollment":5,"completionDate":"2020-10-14"},{"nctId":"NCT00822770","phase":"PHASE1,PHASE2","title":"Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-01","conditions":["Stem Cell Transplantation","Leukemia"],"enrollment":47,"completionDate":"2012-10"},{"nctId":"NCT00322127","phase":"PHASE1","title":"An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2006-06-14","conditions":["Healthy Volunteers"],"enrollment":44,"completionDate":"2015-01-23"},{"nctId":"NCT04058145","phase":"PHASE2","title":"AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2019-09-30","conditions":["Head and Neck Cancer"],"enrollment":0,"completionDate":"2019-10-11"},{"nctId":"NCT03506802","phase":"PHASE1","title":"TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma","status":"WITHDRAWN","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2018-07-10","conditions":["HLA-A*0201 Positive Cells Present","NY-ESO-1 Positive Tumor Cells Present","Recurrent Plasma Cell Myeloma","Refractory Plasma Cell Myeloma"],"enrollment":0,"completionDate":"2019-06-25"},{"nctId":"NCT02522572","phase":"PHASE1,PHASE2","title":"Quantitating the Impact of Plerixafor","status":"UNKNOWN","sponsor":"E. Steve Woodle","startDate":"2015-08","conditions":["Transplants and Implants"],"enrollment":12,"completionDate":"2020-10"},{"nctId":"NCT00903968","phase":"PHASE1,PHASE2","title":"Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2009-06-01","conditions":["Multiple Myeloma"],"enrollment":58,"completionDate":"2016-10"},{"nctId":"NCT02931071","phase":"PHASE2","title":"Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2013-09","conditions":["Fanconi Anemia"],"enrollment":13,"completionDate":"2018-10"},{"nctId":"NCT02416908","phase":"PHASE1,PHASE2","title":"Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2015-06-16","conditions":["Acute Myeloid Leukemia"],"enrollment":40,"completionDate":"2019-06-21"},{"nctId":"NCT03277209","phase":"PHASE1","title":"To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2017-07-25","conditions":["Pancreas Cancer"],"enrollment":2,"completionDate":"2019-12-30"},{"nctId":"NCT02605460","phase":"PHASE2","title":"Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission","status":"UNKNOWN","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2014-02","conditions":["Acute Myeloid Leukemia","Acute Lymphoid Leukemia"],"enrollment":20,"completionDate":"2021-11"},{"nctId":"NCT01146834","phase":"PHASE3","title":"Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2011-03","conditions":["Multiple Myeloma"],"enrollment":47,"completionDate":"2019-02-04"},{"nctId":"NCT02790957","phase":"PHASE2","title":"Plerixafor in Diabetic Wound Healing","status":"TERMINATED","sponsor":"Gian Paolo Fadini","startDate":"2016-06","conditions":["Diabetes","Wounds","Critical Limb Ischemia"],"enrollment":25,"completionDate":"2019-11"},{"nctId":"NCT02682953","phase":"PHASE2","title":"Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2015-10","conditions":["Bone Marrow Transplantation","Hematopoietic Stem Cells","Multiple Myeloma","Lymphoma"],"enrollment":0,"completionDate":"2017-08"},{"nctId":"NCT03547830","phase":"PHASE2","title":"Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2019-04-13","conditions":["Chronic Granulomatous Disease"],"enrollment":17,"completionDate":"2023-01-01"},{"nctId":"NCT01160354","phase":"PHASE1,PHASE2","title":"Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-08","conditions":["Acute Myelogenous Leukemia"],"enrollment":22,"completionDate":"2016-03"},{"nctId":"NCT02179970","phase":"PHASE1","title":"To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers","status":"COMPLETED","sponsor":"CCTU- Cancer Theme","startDate":"2015-06","conditions":["Pancreatic Adenocarcinoma Metastatic","Ovarian Serous Adenocarcinoma","Colorectal Cancer Metastatic"],"enrollment":26,"completionDate":"2018-12-14"},{"nctId":"NCT02695966","phase":"","title":"EVIS - Ex-vivo Assessment of T-lymphocyte Homing in Primary Pancreatic Cancer","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2015-05","conditions":["Pancreatic Cancer"],"enrollment":20,"completionDate":"2018-07"},{"nctId":"NCT01408043","phase":"NA","title":"Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Case Comprehensive Cancer Center","startDate":"2011-10","conditions":["Adult Acute Lymphoblastic Leukemia in Remission","Adult Grade III Lymphomatoid Granulomatosis","Adult Nasal Type Extranodal NK/T-cell Lymphoma","Anaplastic Large Cell Lymphoma","Angioimmunoblastic T-cell Lymphoma","Cutaneous B-cell Non-Hodgkin Lymphoma","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Hepatosplenic T-cell Lymphoma","Nodal Marginal Zone B-cell Lymphoma","Noncutaneous Extranodal Lymphoma","Peripheral T-cell Lymphoma","Recurrent Adult Burkitt Lymphoma","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Adult Diffuse Mixed Cell Lymphoma","Recurrent Adult Diffuse Small Cleaved Cell Lymphoma","Recurrent Adult Grade III Lymphomatoid Granulomatosis","Recurrent Adult Immunoblastic Large Cell Lymphoma","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Adult T-cell Leukemia/Lymphoma","Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent Mycosis Fungoides/Sezary Syndrome","Recurrent Small Lymphocytic Lymphoma","Refractory Chronic Lymphocytic Leukemia","Refractory Hairy Cell Leukemia","Small Intestine Lymphoma","Splenic Marginal Zone Lymphoma","T-cell Large Granular Lymphocyte Leukemia","Testicular Lymphoma","Waldenström Macroglobulinemia"],"enrollment":25,"completionDate":"2016-05"},{"nctId":"NCT01818284","phase":"PHASE2","title":"Plerixafor for Stem Cell Mobilization in Normal Donors","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-10","conditions":["Blood And Marrow Transplantation"],"enrollment":22,"completionDate":"2016-06"},{"nctId":"NCT00807599","phase":"PHASE2","title":"Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-12-10","conditions":["Multiple Myeloma"],"enrollment":67,"completionDate":"2018-07"},{"nctId":"NCT03019809","phase":"PHASE2","title":"A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2016-06","conditions":["Wiskott-Aldrich Syndrome","Hematopoietic Stem Cell Transplantation","Graft Failure"],"enrollment":30,"completionDate":"2019-07"},{"nctId":"NCT02343666","phase":"PHASE1","title":"HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2016-08-15","conditions":["Human Immunodeficiency Virus 1 Positive","Stage I Adult Hodgkin Lymphoma","Stage I Adult Non-Hodgkin Lymphoma","Stage II Adult Hodgkin Lymphoma","Stage II Adult Non-Hodgkin Lymphoma","Stage III Adult Hodgkin Lymphoma","Stage III Adult Non-Hodgkin Lymphoma","Stage IV Adult Hodgkin Lymphoma","Stage IV Adult Non-Hodgkin Lymphoma"],"enrollment":0,"completionDate":""},{"nctId":"NCT01977677","phase":"PHASE1,PHASE2","title":"Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma","status":"COMPLETED","sponsor":"Lawrence Recht","startDate":"2014-11","conditions":["Adult Ependymoblastoma","Adult Giant Cell Glioblastoma","Adult Glioblastoma","Adult Gliosarcoma","Adult Medulloblastoma","Adult Mixed Glioma","Adult Oligodendroglial Tumors","Adult Pineoblastoma","Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)"],"enrollment":30,"completionDate":"2018-09"},{"nctId":"NCT01319864","phase":"PHASE1","title":"POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients","status":"COMPLETED","sponsor":"Seattle Children's Hospital","startDate":"2011-03","conditions":["Relapsed/Refractory AML","Relapsed/Refractory ALL","Secondary AML/MDS","Acute Leukemia of Ambiguous Lineage","AML","ALL"],"enrollment":20,"completionDate":"2016-06-28"},{"nctId":"NCT01182675","phase":"PHASE2","title":"Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2010-08","conditions":["Severe Combined Immunodeficiency"],"enrollment":7,"completionDate":"2013-09"},{"nctId":"NCT02069080","phase":"EARLY_PHASE1","title":"Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-02-20","conditions":["Cancer"],"enrollment":2,"completionDate":"2018-07-10"},{"nctId":"NCT01352650","phase":"PHASE1","title":"Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2011-06-17","conditions":["Acute Myeloid Leukemia"],"enrollment":71,"completionDate":"2016-12-27"}],"_emaApprovals":[{"date":"2009-07-30","status":"Authorised","company":"Sanofi B.V."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT00103610","NCT00103662"],"administration":{"route":"Subcutaneous","formulation":"Injection, Solution","formulations":[{"form":"INJECTION","route":"SUBCUTANEOUS","productName":"PLERIXAFOR"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Plerixafor"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"plerixafor"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Mozobil"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Plerixafor"},{"form":"SOLUTION","route":"SUBCUTANEOUS","productName":"Plerixafor"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000177944","MMSL":"159539","NDDF":"012924","UNII":"S915P5499N","VUID":"4028232","CHEBI":"CHEBI:125354","VANDF":"4028232","INN_ID":"8513","RXNORM":"733003","UMLSCUI":"C1955474","chemblId":"CHEMBL5402188","ChEMBL_ID":"CHEMBL18442","KEGG_DRUG":"D08971","DRUGBANK_ID":"DB06809","PUBCHEM_CID":"65015","SNOMEDCT_US":"442206008","IUPHAR_LIGAND_ID":"844","MESH_SUPPLEMENTAL_RECORD_UI":"C088327"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2008-","companyName":"Genzyme","relationship":"Original Developer"},{"period":"2009","companyName":"Sanofi B.V.","relationship":"EMA Licensee"}],"pharmacokinetics":{"source":"FDA label","halfLife":"5.3 hours"},"publicationCount":1013,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L03AX16","allCodes":["L03AX16"]},"biosimilarFilings":[],"originalDeveloper":"Genzyme","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":9,"_genericFilersChecked":true,"genericManufacturerList":["Amneal","Dr Reddys","Eugia Pharma","Gland","Hetero Labs Ltd Vi","Meitheal","Msn","Teva Pharms Usa Inc","Zydus Pharms"],"status":"active","companyName":"Genzyme","companyId":"sanofi","modality":"Small Molecule","firstApprovalDate":"2008","aiSummary":"","enrichmentLevel":4,"visitCount":4,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-07-24T00:00:00.000Z","mah":"MSN","brand_name_local":null,"application_number":"ANDA211901"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-01-30T00:00:00.000Z","mah":"ZYDUS PHARMS","brand_name_local":null,"application_number":"ANDA208980"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-05-03T00:00:00.000Z","mah":"GLAND","brand_name_local":null,"application_number":"ANDA206644"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-03-26T00:00:00.000Z","mah":"EUGIA PHARMA","brand_name_local":null,"application_number":"ANDA213672"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-06-16T00:00:00.000Z","mah":"HETERO LABS LTD VI","brand_name_local":null,"application_number":"ANDA217560"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:52:28.520469+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}